Trending
NFLX 
$186.35  $2.87 
AAPL 
$137.59  $0.24 
AMZN 
$2,151.82  $5.44 
TSLA 
$663.90  $45.52 
GOOG 
$2,186.26  $28.65 

(NASDAQ:MREO) is up 10% on news of positive phase 2 data.

(NASDAQ:MREO) is up 10% on news of positive phase 2 data.

Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period

Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease

No safety signals were associated with alvelestat

Conference Call Today at 10:30 a.m. ET

https://www.globenewswire.com/news-release/2022/05/09/2438434/0/en/Mereo-BioPharma-announces-Positive-Top-Line-Efficacy-and-Safety-Data-from-ASTRAEUS-Phase-2-Trial-of-Alvelestat-in-Alpha-1-Antitrypsin-Deficiency-associated-Emphysema.html

JOIN OUR NEWSLETTER

Signup today for free and be the first to get notified of breaking news.

Recent News

Follow Us

Add New Playlist